Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Lease Payments

Lease Payments at other companies

Zymeworks logo
ZymeworksZYME
$1.09M+3.9%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.02B-54.5%

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeasePayments.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's lease payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's lease payments?
ADMA Biologics (ADMA) reported lease payments of $400K in Q1 2026.
How has ADMA Biologics's lease payments changed year-over-year?
ADMA Biologics's lease payments decreased by 33.3% year-over-year, from $600K to $400K.
What is the long-term trend for ADMA Biologics's lease payments?
Over 2 years (2023 to 2025), ADMA Biologics's lease payments has grown at a 0.0% compound annual growth rate (CAGR), from $2.4M to $2.4M.
What does lease payments mean?
The actual cash outflows made to lessors for the use of assets under operating lease agreements. This metric is essential for understanding the company's fixed cash obligations and liquidity requirements.